ClinConnect ClinConnect Logo
Search / Trial NCT06907667

Study of the Impact of Time of Vaccination on Response to Influenza Vaccine in Patients With Chronic Renal Failure

Launched by CENTRE HOSPITALIER UNIVERSITAIRE DE NICE · Mar 26, 2025

Trial Information

Current as of August 24, 2025

Not yet recruiting

Keywords

Influenza Chronic Renal Insufficiency Vaccination

ClinConnect Summary

The CHRONOVAX 2 trial is studying how the timing of the influenza vaccine affects the immune response in patients with chronic renal failure. This is important because individuals with kidney issues may not respond as well to vaccines, and understanding the best time to vaccinate them could help improve their protection against the flu.

To participate in this study, individuals need to be at least 18 years old and have chronic renal failure (stage 4 or 5), be on dialysis, or have received a kidney transplant. They should also need the flu vaccine. However, people who are allergic to the flu vaccine or egg proteins, have recently had a flu shot, are currently ill, or are undergoing treatments that could affect their immune response may not be eligible. Participants will be asked to give their consent and will help researchers learn more about how to better protect people with kidney issues from influenza.

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • Chronic renal failure patient at stage 4 or 5 (i.e. estimated GFR \< 30mL/min/1.73m2); or Dialysis patient; or renal transplant patient regardless of GFR;
  • Age ≥ 18 years;
  • Indication for influenza vaccination;
  • Express free and informed consent.
  • Exclusion Criteria:
  • Known hypersensitivity to influenza vaccine or egg proteins;
  • Previous influenza vaccination for the current season;
  • Current infection;
  • Current acute illness;
  • * Treatments with a major impact on vaccine response:
  • Treatment of rejection within the previous 3 months;
  • Renal transplantation with induction performed within the previous 6 months;
  • Immunosuppressive treatment including CTLA4 agonist, complement inhibitor, anti-CD20;
  • Treatments that may distort the serological response: Polyvalent immunoglobulin infusion within the preceding 3 months;
  • Vulnerable persons (minors, adults under guardianship or trusteeship, persons deprived of their liberty, persons unable to speak French);
  • Subjects not affiliated to Social Security.

About Centre Hospitalier Universitaire De Nice

The Centre Hospitalier Universitaire (CHU) de Nice is a leading academic medical center located in Nice, France, dedicated to advancing healthcare through innovative research and clinical excellence. As a prominent sponsor of clinical trials, CHU de Nice is committed to enhancing patient care by conducting rigorous studies that explore new therapies and treatment modalities across various medical disciplines. With a focus on collaboration, the center integrates cutting-edge technology and interdisciplinary expertise to ensure the highest standards of research integrity and patient safety. CHU de Nice plays a vital role in the development of evidence-based medicine, contributing significantly to the global medical community.

Locations

Nice, Alpes Maritimes, France

Patients applied

0 patients applied

Trial Officials

GOSSET Clément, MD

Principal Investigator

CHU NICE

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported